25,000 shares issuable through warrants count toward a reported stake in Dermata Therapeutics (DRMA).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Bigger Capital Fund, LP and District 2 Capital Fund LP have reported beneficial ownership in Dermata Therapeutics (DRMA) via a Schedule 13G filing. Michael Bigger may be deemed to beneficially own approximately 8.36% of DRMA's common stock, totaling 414,064 shares, which includes 25,000 shares issuable from Pre-Funded Warrants.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.